New Pathway to Treat Breast Cancer Discovered
Medindia reports on recent studies done on the databases related to breast cancer and the analysis shows that beclin 1, an autophagy gene, with a reduced activity was related to a higher occurrence of triple-negative breast cancer. The low beclin 1 expression leads to a higher risks of having triple-negative breast cancer as Director of the Center for Autophagy Research, Dr. Beth Levine comments. The data research clearly shows that a lower beclin 1 activity contributes to breast cancer and poor survival chances. This is why therapies that boost beclin 1 activity may be beneficial in breast cancer.
Dr. Levine's research team shows that a lower level of beclin 1 activity relates to the worse outcomes. Thus, as zeenews reports, this could become the basis of a new therapy for breast cancer patients. Already, there are several approved drugs that increase beclin 1 activity and are used for other types of cancer. These classes of drugs include protein kinase B (AKT), beclin 1/BCL-2 binding, and epidermal growth factor receptor (EGFR). The gene and its role in cancer, neurodegenerative diseases, aging and other infections are already being researched upon. An increased beclin 1 activity could become a new treatment for breast cancer patients.
Dr. Xie's UT Southwestern lab is focusing on therapies to improve cancer treatments based on statistical and computational analysis of the clinical and biological data available, as The Health Site reports. There are new therapies coming up based on new chemotherapy drugs, old drugs and following new hormonal therapies. These new developments look into the genetic impact on breast cancer development. As each women fighting breast cancer reacts differently, it is true that they will need complete emotional support as well as the latest information to benefit. The breast cancer is now linked to the deficiency in a gene.
